Age-standardized DALYs (per 100,000)
Distribution of years of life lost by major cause group
Adult mortality rate (probability of dying between 15 and 60 years per 1000 population)
Distribution of causes of death among children aged < 5 years (%)
Number of maternal deaths
Maternal mortality ratio (per 100 000 live births)
Stillbirth rate (per 1000 total births)
Life expectancy at age 60 (years)
nMx - age-specific death rate between ages x and x+n
ndx - number of people dying between ages x and x+n
nqx - probability of dying between ages x and x+n
lx - number of people left alive at age x
nLx - person-years lived between ages x and x+n
Tx - person-years lived above age x
ex - expectation of life at age x
Age-standardized NCD mortality rate  (per 100 000 population)
Mortality rate for 5-14 year-olds (probability of dying per 1000 children aged 5-14 years)
Number of deaths among children ages 5 to 9 years
Number of infant deaths (between birth and 11 months)
Infant mortality rate (between birth and 11 months per 1000 live births)
Mortality rate among children ages 5 to 9 years (per 1000 children aged 5)
Number of neonatal deaths (0 to 27 days)
Neonatal mortality rate (0 to 27 days) per 1000 live births) (SDG 3.2.2)
Number of deaths among children under-five
Under-five mortality rate (per 1000 live births) (SDG 3.2.1)
Number of deaths among children ages 10 to 14 years
Mortality rate among children ages 10 to 14 years (per 1000 children aged 10)
Skilled health professionals density (per 10 000 population)
Estimated direct deaths from major conflicts (per 100 000 population)
Average of 13 International Health Regulations core capacity scores, 1st version of the questionnaire
Average death rate due to natural disasters (per 100 000 population)
Life expectancy at birth (years)
Healthy life expectancy (HALE) at birth (years)
Healthy life expectancy (HALE) at age 60 (years)
Mortality rate attributed to unintentional poisoning (per 100 000 population)
Average of 13 International Health Regulations core capacity scores, SPAR version, 1st edition
Crude suicide rates (per 100 000 population)
Girls aged 15 years old that received the recommended doses of HPV vaccine (%)
Women of reproductive age (aged 15-49 years) who have their need for family planning satisfied with modern methods (%)
Adolescent birth rate (per 1000 women)
Reported number of people requiring interventions against NTDs
Births attended by skilled health personnel (%)
Concentrations of fine particulate matter (PM2.5)
Ambient and household air pollution attributable death rate (per 100 000 population)
Ambient and household air pollution attributable death rate (per 100 000 population, age-standardized)
New HIV infections (per 1000 uninfected population)
Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) (SDG 3.9.2)
Maternal mortality ratio (per 100 000 live births) - Country reported estimates
Donor disbursements (Million, constant 2009 US$)
Antenatal care coverage - at least four visits (%)
Radiotherapy units (per 1 000 000 population)
Donor commitments (Million, constant 2009 US$)
Number of licensed qualified surgeons actively working
Number of licensed qualified anaesthesiologists actively working
Number of licensed qualified obstetricians actively working
Biomedical engineers density (per 10 000 population)
Number of biomedical engineers
Biomedical technicians density (per 10 000 population)
Number of biomedical technicians
Status of indigenous malaria cases
Estimated number of malaria cases
Estimated malaria incidence (per 1000 population at risk)
Number of indigenous malaria cases
Estimated number of malaria deaths
Estimated malaria mortality rate (per 100 000 population)
Smear-positive tuberculosis case-detection rate (%)
Tuberculosis - new and relapse cases (TB_c_newinc)
Minimum legal drinking age
New cases: pulmonary smear-negative
New cases: pulmonary smear unknown/not done
New cases: other
Retreatment cases: treatment after failure (pulmonary smear and/or culture positive)
Retreatment cases: treatment after default (pulmonary smear and/or culture positive)
Retreatment cases: other
Smear-positive tuberculosis treatment-success rate (%)
Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases
Confirmed cases of MDR-TB
Confirmed cases of MDR-TB started treatment for MDR-TB (%)
Estimated MDR-TB cases among notified pulmonary TB cases
Number of prevalent tuberculosis cases
Second-line drug susceptibility testing (DST) available
Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population)
Laboratories providing tuberculosis diagnostic services using culture (per 5 million population)
Laboratories providing drug susceptibility testing (DST) (per 5 million population)
Total number of notified TB cases
Tuberculosis effective treatment coverage (%)
Treatment success rate: new TB cases
Treatment success rate: previously treated TB cases
Treatment success rate: HIV-positive TB cases
Treatment success rate for patients treated for MDR-TB (%)
Treatment success rate: XDR-TB cases
Confirmed cases of RR-/MDR-TB
Cases started on MDR-TB treatment
Previously treated cases tested for RR-/MDR-TB (%)
New cases tested for RR-/MDR-TB (%)
TB patients with known HIV status (%)
Tested TB patients HIV-positive (%)
Estimated number of MDR/RR-TB incident cases
Number of deaths due to tuberculosis, excluding HIV
Deaths due to tuberculosis among HIV-negative people (per 100 000 population)
Number of incident tuberculosis cases
Incidence of tuberculosis (per 100 000 population per year)
Incidence of tuberculosis (per 100 000 population) (HIV-positive cases)
Number of incident tuberculosis cases,  (HIV-positive cases)
Tuberculosis treatment coverage
Number of incident tuberculosis cases in children aged 0 - 14
Tuberculosis - new and relapse cases
New or unknown treatment history cases: Pulmonary, bacteriologically confirmed
New cases: Pulmonary, smear-positive
New or unknown treatment history cases: Pulmonary, clinically diagnosed
New cases: extrapulmonary
Relapse cases: Pulmonary, bacteriologically confirmed
Relapse cases: Pulmonary, clinically diagnosed
Relapse cases: extrapulmonary
Relapse cases (pre-2013 definition)
Previously treated  cases, excluding relapse
Treatment history unknown
New cases: Pulmonary, smear-negative/unknown/not done and other new cases
Children aged <5 years wasted for age (%)
Low birth weight, prevalence (%)
Low birth weight (in thousands)
Infants exclusively breastfed for the first six months of life (%)
Measles-containing-vaccine second-dose (MCV2) immunization coverage by the nationally recommended age (%)
Pneumococcal conjugate vaccines (PCV3) immunization coverage among 1-year-olds (%)
Rotavirus vaccines completed dose (RotaC) immunization coverage among 1-year-olds (%)
Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%)
Hepatitis B (HepB3) immunization coverage among 1-year-olds (%)
Hib (Hib3) immunization coverage among 1-year-olds (%)
Polio (Pol3) immunization coverage among 1-year-olds (%)
Measles-containing-vaccine first-dose (MCV1) immunization coverage among 1-year-olds (%)
Number of reported deaths from cholera
Number of reported cases of cholera
Cholera case fatality rate
Poliomyelitis - number of reported cases
Diphtheria - number of reported cases
Pertussis - number of reported cases
Total tetanus - number of reported cases
Yellow fever - number of reported cases
Mumps - number of reported cases
Congenital Rubella Syndrome - number of reported cases
Neonatal tetanus - number of reported cases
Total rubella - number of reported cases
Measles - number of reported cases
Number of new leprosy cases
Number of leprosy cases registered for treatment (prevalence)
Number of new leprosy cases with G2D
Number of new leprosy cases among children (less than 15 years of age)
Number of new leprosy cases with G2D among children (less than 15 years of age)
Number of new leprosy cases among females
Number of pigs in the country
Presence of roaming backyard pigs
New leprosy cases with G2D rate per 1 000 000 population
New leprosy case detection rate per 1 000 000 population
Leprosy registered prevalence rate per 1 000 000 population
New leprosy child case detection rate (less than 15 years of age) per 1 000 000 child population
Status of endemicity of Taenia solium
Distribution of years of life lost by broader causes (%) - Injuries
Preterm birth rate (per 100 live births)
Deaths due to HIV/AIDS (per 100 000 population)
Births by caesarean section (%)
Completeness of cause-of-death data (%)
Hospital beds (per 10 000 population)
Hepatitis B surface antigen (HBsAg) prevalence among children under 5 years (%)
Age-standardized death rates, colon and rectum cancers, per 100,000
Age-standardized death rates, oesophagus cancer, per 100,000
Age-standardized death rates, alcohol use disorders, per 100,000
Age-standardized death rates, mouth and oropharynx cancer, per 100,000
Age-standardized death rates, falls, per 100,000
Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000
Age-standardized death rates (15+ years), poisoning, per 100,000
Age-standardized death rates, fires, per 100,000
Age-standardized death rates (15+ years), violence, per 100,000
Age-standardized death rates, drownings, per 100,000
Age-standardized death rates, violence, per 100,000
Age-standardized death rates, self-inflicted injury, per 100,000
Age-standardized death rates, road traffic accidents, per 100,000
Age-standardized death rates, liver cirrhosis, per 100,000
Age-standardized death rates, breast cancer, per 100,000
Age-standardized death rates, liver cancer, per 100,000
Age-standardized death rates, poisoning, per 100,000
National drinking guidelines, 2010
Monitoring
Treatment, services
Production in 1000s hectolitres
Imports in 1000s hectolitres
Sales of beer in 1000s hectolitres
Sales of wine in 1000s hectolitres
Exports of wine (grape) in 1000s hectolitres
Exports of spirits in 1000s hectolitres
Exports of beer (barley) in 1000s hectolitres
Sales of spirits in 1000s hectolitres
Perceived trend in production
Perceived trend in imports
Perceived trend in sales
Perceived trend in exports
Point prevalence (%), drug use disorders, 15+ years
Point prevalence (%), alcohol use disorders, 15+ years
Age-standardized death rates, cerebrovascular disease, per 100,000
Age-standardized death rates, diabetes mellitus, per 100,000
Age-standardized death rates, ischaemic heart disease, per 100,000
Age-standardized death rates, other unintentional injuries, per 100,000
Age-standardized death rates, prematurity and low birth rate, per 100,000
Age-standardized DALYs, alcohol use disorders, per 100,000
Age-standardized DALYs, breast cancer, per 100,000
Age-standardized DALYs, cerebrovascular disease, per 100,000
Age-standardized DALYs, colon and rectum cancers, per 100,000
Age-standardized DALYs, diabetes mellitus, per 100,000
Age-standardized DALYs, drownings, per 100,000
Age-standardized DALYs, falls, per 100,000
Age-standardized DALYs, fires, per 100,000
Age-standardized DALYs, ischaemic heart disease, per 100,000
Age-standardized DALYs, liver cancer, per 100,000
Age-standardized DALYs, liver cirrhosis, per 100,000
Age-standardized DALYs, mouth and oropharynx cancer, per 100,000
Age-standardized DALYs, oesophagus cancer, per 100,000
Age-standardized DALYs, other unintentional injuries, per 100,000
Age-standardized DALYs, poisoning, per 100,000
Age-standardized DALYs, road traffic accidents, per 100,000
Age-standardized DALYs, self-inflicted injury, per 100,000
Age-standardized DALYs, violence, per 100,000
Age-standardized DALYs, prematurity and low birth rate, per 100,000
Social costs of alcohol use in millions US$
Age-standardized death rates, alcohol and drug use disorders, per 100 000
Age-standardized DALYs, alcohol and drug use disorders, per 100 000
Hospital discharges, alcoholic liver disease, per 100,000
Alcoholic psychosis, incidence, per 100,000
Alcohol-related disease mortality, per 100,000 (15+ years)
Alcohol-related injury mortality, per 1,000
Excise tax as a per cent of the total retail price for 1 litre of pure alcohol
Prices for alcoholic beverages (average, US$)
Excise tax as a per cent of the retail price of alcoholic beverages
Alcohol, patterns of drinking score
Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol)
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol)
Alcohol, tourist consumption (in litres of pure alcohol)
Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol)
Alcohol, drinkers only per capita (15+)consumption in litres of pure alcohol
Alcohol, abstainers lifetime (%)
Alcohol, former drinkers (%)
Alcohol, consumers past 12 months (%)
Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI
Alcohol-related road traffic crashes, per 100,000 population
Alcohol-related road traffic crashes (% of all traffic crashes)
Cautions and arrests for drink-driving, per 100,000 population
Alcoholic beverage legally defined
Adopted written national policy on alcohol
Advertising restrictions on cable television
Standard drink measures, in grams per unit
Advertising restrictions on national television
Advertising restrictions on national radio
Advertising restrictions on local radio
National legislation to prevent illegal alcohol
Advertising restrictions on billboards
Advertising restrictions on the internet
Advertising restrictions in print media
Advertising restrictions at cinemas
Advertising restrictions at point-of-sale
Restrictions on product placement on national television
Restrictions on product placement on cable television
Random breath testing (RBT) use
Excise tax on alcoholic beverages
Duty paid or excise stamp on alcohol container
Value-added tax (VAT) on alcohol (%)
Health warning labels on alcohol containers
Health warning labels on alcohol advertising
Off-premise sales restrictions on outlet density
Off-premise sales restrictions at petrol stations
Off-premise sales restrictions on days
Off-premise sales restrictions on hours
Off-premise sales restrictions at specific events
Off-premise sales restrictions on places
On-premise sales restrictions on outlet density
On-premise sales restrictions on days
On-premise sales restrictions on hours
On-premise sales restrictions on places
Restrictions on sales promotion from producers (parties, events)
On-premise sales restrictions to intoxicated persons (archived)
Restrictions on sales promotion from owners of pubs and bars (alcohol for free)
Restrictions on sponsorship of youth events
On-premise sales restrictions at specific events
Restrictions on sponsorship of sporting events
Restrictions on sales promotion from retailers (sales below cost)
Government monopoly on production
Government monopoly on retail sales
Licence required for production
Licence required for retail sales
Restrictions on alcohol use in public places
Alcohol use disorders (15+), 12 month prevalence (%) with 95%
Awareness activities
Road traffic injuries, age-standardized death rates (15+), per 100,000 population
Liver cirrhosis, age-standardized death rates (15+), per 100,000 population
Age limits on-premise service
Alcohol, consumption of pure alcohol by type of beverage (%)
Legal blood alcohol concentration (BAC) limits
Annual revenues from alcohol excise tax in millions US$
Alcohol expenditure as a per cent of total household expenditure
Alcoholic excise tax revenue as a per cent of government revenue
Alcohol, abstainers past 12 months (%)
Alcohol, heavy episodic drinking (15+), drinkers only, past 30 days (%)
Alcohol, total per capita (15+) consumption (in litres of pure alcohol) (SDG Indicator 3.5.2)
Training in screening and brief interventions for alcohol problems
Designation of alcohol tax revenues to health services
Counselling to pregnant women with alcohol problems
Alcohol, total  (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025
15-19 years old abstainers, lifetime (%)
15-19 years old former drinkers (%)
Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities)
Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images (see E14b_movies_anti_tob_ads)
Subnational bans on tobacco advertising, promotion and sponsorship
Sponsored events
Ban on entities other than tobacco companies/tobacco industry publicizing the Corporate Social Responsibility� activities of the tobacco companies
Ban on tobacco companies/tobacco industry publicizing their “Corporate Social Responsibility” activities
Youth indicator 1 definition
Adult smokeless tobacco use indicator definition
Representativeness of survey of adults - smokeless
Representativeness of survey of youth - smokeless
Compliance with regulations on smoke-free environments (national legislation)
Compliance with bans on promotion and sponsorship
Comprehensive bans in place subnationally
Adult indicator 1 rate
Youth indicator 1 rate
Youth smokeless tobacco use indicator rate
Alcohol, average daily intake in grams among drinkers with 95%CI
Cautions and arrests for public drunkenness, per 100,000 population
Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI
Framework of national alcohol policy
Central coordinating entity for alcohol policy implementation
Sectors represented in national alcohol policy
Advertising restrictions on social media
Restrictions on product placement in films/movies
Government support for community action
Penalties for drink driving
Level of taxation adjusted for inflation
Number of standard alcoholic drinks displayed on containers
Consumer information about calories, additives, etc on containers
Alcohol content displayed on containers
Penalties for marketing infringements
15-19 years old heavy episodic drinkers (population), % with 95%CI
Alcohol-attributable fractions (15+), liver cirrhosis deaths (%)
Alcohol-attributable Years of Life Lost (YLL) score
Age limits off-premise sales
Psychiatrists working in mental health sector (per 100 000 population)
Beds in mental hospitals (per 100 000 population)
Beds for mental health in general hospitals (per 100 000 population)
Alcohol, heavy episodic drinking (15+) past 30 days (%), age-standardized with 95%CI
Age-standardized suicide rates (per 100 000 population)
Ban on sale of smokeless tobacco products
System for monitoring alcohol-related harm
Counselling to children in families with alcohol problems
Data collection on alcohol-related health indicators
Mental health plan
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark (see W21_emissions_quant_A)
Complete ban on tobacco vending machines
Ban on advertising: Point of sale
Appearance of tobacco products in TV and/or films
Compliance with bans on direct advertising
Adult survey age range - smokeless
Adult indicator 1 definition
Youth smokeless tobacco use indicator definition
Representativeness of youth survey
Name of survey of adults - smokeless
Name of survey of youth
Process evaluation was employed to assess implementation
Youth survey age range
Adult indicator 2 rate
Adult smokeless tobacco use indicator rate
Action Plan for implementation of alcohol policy
Adopted written national policy on alcohol, year revised
Sobriety checkpoints
National guidelines for the prevention and reduction of alcohol-related harm in schools
15-19 years old heavy episodic drinkers (drinkers only), %
Alcohol-attributable fractions (15+), road traffic crash deaths (%)
Alcohol-attributable fractions, all-cause deaths (%)
15-19 years old, current drinkers (%)
Stand-alone law for mental health
Mental health units in general hospitals (per 100 000 population)
Mental health outpatient facilities (per 100 000 population)
Community-based interventions/projects involving stakeholders
Prevention/counselling at workplaces for those with alcohol problems
Interventions/projects actively involving young people and civil society
Mental health policy
Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2016
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI, 2010 ( already in archive)
Adult survey age range
Youth survey age range - smokeless
Level of adoption of national alcohol policy
Adopted written national policy on alcohol, year adopted
Price measures
Detection of marketing infringements
Server training
Public-funded alcohol research/monitoring programmes
Public funds designated for alcohol research/monitoring programmes, in Euros
National treatment policy for alcohol use disorders
National surveys on drink-driving
Persons with alcohol use disorders receiving treatment (%)
Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI
Representativeness of survey of adults
Name of survey of adults
Name of survey of youth - smokeless
Adult indicator 2 definition
National guidelines for alcohol problem prevention and counselling at workplaces
Psychologists working in mental health sector (per 100 000 population)
Nurses working in mental health sector (per 100 000 population)
Social workers working in mental health sector (per 100 000 population)
Mental hospitals (per 100 000 population)
Regular reports from national monitoring systems
15-19 years old total alcohol consumption in litres of pure alcohol
Mental hospital admissions (per 100 000 population)
Outpatient visits (per 100 000 population)
Mental health units in general hospitals admissions (per 100 000 population)
Stand-alone policy or plan for mental health
Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place
Ban on display of tobacco products at points of sale
Law requires fines for violations of indirect advertising bans,2015
Law requires fines for violations of direct advertising bans, 2015
Compliance of ban on smoking in HEALTH-CARE FACILITIES
Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES
Compliance of ban on smoking in UNIVERSITIES
Compliance of ban on smoking in INDOOR OFFICES
Compliance of ban on smoking in RESTAURANTS
Compliance of ban on smoking in PUBS AND BARS
Compliance of ban on smoking in PUBLIC TRANSPORT
Compliance of ban on smoking in GOVERNMENT FACILITIES
Compliance of ban on sponsored events
Compliance of ban on appearance of tobacco products in TV and/or films
Compliance of ban on appearance of tobacco brands in TV and/or films (product placement)
Compliance of ban on brand name of non-tobacco products used for tobacco product
Compliance of ban on non-tobacco goods AND services identified with tobacco brand names
Compliance of ban on promotional discounts
Compliance of ban on free distribution of tobacco products in the mail or through other means
Compliance of ban on advertising at point of sale
Compliance of ban on advertising on billboards and outdoor advertising
Compliance of ban on advertising on local magazines and newspapers
Compliance of ban on advertising on national TV and radio
Level of enforcement of BAC limits
Legislation on alcohol testing at workplaces
Standard drink defined
National systems for monitoring alcohol consumption and harms
National surveys on adult alcohol consumption
National surveys on youth alcohol consumption
Heavy episodic drinking (youth 15 -19 years) past 30 days (%)
Cancer, age-standardized death rates (15+), per 100,000 population
Alcohol-attributable fractions (15+), cancer deaths
National legislation to prevent illegal alcohol sales
Heavy episodic drinking (youth 15 -19 years), drinkers only, past 30 days (%)
15-years old any alcoholic beverage consumed in past 12 months, (%)
15-years old any alcoholic beverage consumed in past 30 days, (%)
15-years old, any alcoholic beverage consumed at least once a week, (%)
15-years old first drink at 13 years or younger, (%)
Publication year of the policy or plan (latest revision)
Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI
Alcohol, tourist consumption (in litres of pure alcohol) (three-year average)
Existence of a formal pre-hospital care system
Gross national income per capita (Atlas method)
Income level
Population
Child maltreatment: Extent of implementation of home-visiting programmes
Youth violence: Extent of implementation of life-skills and social development programmes
Intimate partner violence: Extent of implementation  of dating violence prevention programmes
Elder abuse: Extent of implementation  of caregiver-support programmes
Extent of implementation of  mental health services for victims of all types of violence
Extent of implementation of child protection services
Extent of implementation of medico-legal services for victims of sexual violence
Number of registered vehicles
Distribution of road traffic deaths by type of road user (%)
Blood Alcohol Concentration (BAC) limit for drivers
Existence of a national seat-belt law
Applicability of seat-belt law to all occupants
Seat-belt wearing rate (%)
Existence of a national child-restraint law
Existence of national speed limits
Maximum speed limits
Law requires helmet to be fastened
Applicability of national motorcycle helmet law to all occupants
Existence of a national drink-driving law
Definition of drink-driving by BAC
Attribution of road traffic deaths to alcohol (%)
Existence of a road safety lead agency
Existence of a national road safety strategy
Availability of funding for national road safety strategy
Existence of a universal access telephone number for pre-hospital care
Vehicle standards
Estimated number of road traffic deaths
Estimated road traffic death rate (per 100 000 population)
Estimates of number of homicides
Estimates of rates of homicides per 100 000 population
Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in the previous 12 months
Proportion of ever-partnered women and girls aged 15–49 years subjected to physical and/or sexual violence by a current or former intimate partner in their lifetime
Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%)
Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines
Estimated number of tests performed where results were received by a person (testing volume), estimated number per 1000 population
Reported number of tests performed where results were received by a person (testing volume), reporting period
Reported number of tests performed where results were received by a person (testing volume)
Reported number of children receiving antiretroviral therapy
Estimated number of children needing antiretroviral therapy based on WHO methods
Estimated antiretroviral therapy coverage among children
Estimated number of people (all ages) living with HIV
Number of people dying of HIV-related causes
Reported number of people receiving antiretroviral therapy
Estimated antiretroviral therapy coverage among people living with HIV (%)
Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission
Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission
Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission
Prevalence of HIV among adults aged 15 to 49 (%)
Number of new HIV infections
Water, sanitation and hygiene attributable deaths ('000) in children under 5 years
Water, sanitation and hygiene attributable deaths per 100'000 capita
Water, sanitation and hygiene  attributable deaths per 100'000 children under 5 years
Water, sanitation and hygiene attributable DALYs ('000)
Water, sanitation and hygiene attributable DALYs ('000) in children under 5 years
Water, sanitation and hygiene attributable DALYs per 100'000 capita
Water, sanitation and hygiene  attributable DALYs per 100'000 children under 5 years
UV radiation
UV radiation attributable deaths
UV radiation attributable deaths per 100'000 capita
UV radiation attributable DALYs ('000)
UV radiation attributable DALYs per 100'000 capita
Population using solid fuels (%)
Age-standardized deaths attributable to the environment (per 100 000 population)
Disability-adjusted life years (DALYs) attributable to the environment
Age-standardized DALYs attributable to the environment (per 100 000 population)
Deaths attributable to the environment
Disability-adjusted life years (DALYs) attributable to the environment (%)
Deaths attributable to the environment (%)
DALYs attributable to ambient air pollution (age-standardized)
Access restrictions
Restriction and inspection of facilities
Information requirements
Safety requirements
Training requirements
Existence of national regulation
Existence of subnational regulation
Ambient air pollution attributable DALYs (please see AIR_7)
Population using at least basic drinking-water services (%)
Population using safely managed drinking-water services (%)
Population using at least basic sanitation services (%)
Population using safely managed sanitation services (%)
Population with basic handwashing facilities at home (%)
Population practising open defecation (%)
Ambient air pollution attributable death rate (per 100 000 population)
Ambient air pollution attributable deaths
Ambient air pollution attributable death rate (per 100 000 population, age-standardized)
Ambient air pollution attributable DALYs
Ambient air pollution attributable DALYs  in children under 5 years
Ambient air pollution attributable DALYs  (per 100 000 population)
Ambient air pollution attributable DALYs  (per 100 000 population, age-standardized)
Ambient air pollution attributable YLLs
Ambient air pollution attributable YLL in children under 5 years
Ambient air pollution attributable deaths in children under 5 years
Ambient air pollution  attributable deaths per 100'000 children under 5 years
Ambient air pollution  attributable DALYs per 100'000 children under 5 years
Ambient air pollution attributable DALYs in children under 15 years
Ambient air pollution attributable deaths in children under 15 years
Ambient air pollution attributable YLL in children under 15 years
Household air pollution attributable deaths
Household air pollution attributable death rate (per 100 000 population)
Household air pollution attributable death rate (per 100 000 population, age-standardized)
Household air pollution attributable DALYs
Household air pollution attributable DALYs (per 100 000 population)
Household air pollution attributable DALYs (per 100 000, age-standardized)
Household air pollution attributable deaths in children under 5 years
Household air pollution attributable DALYs in children under 5 years
Household air pollution attributable deaths in children under 15 years
Household air pollution attributable DALYs in children under 15 years
Attributable fraction of diarrhoea to inadequate hygiene
Number of diarrhoea deaths from inadequate hygiene
Number of diarrhoea DALYs from inadequate hygiene
Attributable fraction of diarrhoea to inadequate water, sanitation and hygiene
Number of diarrhoea deaths from inadequate water, sanitation and hygiene
Number of diarrhoea DALYs from inadequate water, sanitation and hygiene
SDG 3.9.2 WASH deaths
Exclusive breastfeeding under 6 months (%)
Prevalence of anaemia in children aged 6–59 months (%)
Number of children aged 6–59 months with anaemia (thousands)
Number of women of reproductive age (aged 15-49 years) with anaemia (thousands)
Number of non-pregnant women (aged 15-49 years) with anaemia (thousands)
Number of pregnant women (aged 15-49 years) with anaemia (thousands)
Prevalence of anaemia in pregnant women (aged 15-49) (%)
Prevalence of anaemia in non-pregnant women (aged 15-49) (%)
Prevalence of anaemia in women of reproductive age (aged 15-49) (%)
Deaths in children aged <5 years, by cause
Deaths in children aged <5 years, by cause (per 1 000 live births)
Mean BMI (kg/m&#xb2;) (crude estimate)
Mean fasting blood glucose (mmol/l) (crude estimate)
Mean systolic blood pressure (crude estimate)
Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate)
Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate)
Mean systolic blood pressure (age-standardized estimate)
Prevalence of obesity among adults, BMI &GreaterEqual; 30 (age-standardized estimate) (%)
Prevalence of obesity among adults, BMI &GreaterEqual; 30 (crude estimate) (%)
Prevalence of underweight among adults, BMI < 18.5 (age-standardized estimate) (%)
Prevalence of underweight among adults, BMI < 18.5 (crude estimate) (%)
Mean BMI (kg/m&#xb2;) (age-standardized estimate)
Prevalence of overweight among adults, BMI &GreaterEqual; 25 (age-standardized estimate) (%)
Prevalence of overweight among adults, BMI &GreaterEqual; 25 (crude estimate) (%)
Prevalence of overweight among children and adolescents, BMI > +1 standard deviations above the median (crude estimate) (%)
Prevalence of obesity among children and adolescents, BMI > +2 standard deviations above the median (crude estimate) (%)
Prevalence of thinness among children and adolescents, BMI < -2 standard deviations below the median (crude estimate) (%)
Raised fasting blood glucose (>= 7.0 mmol/L) (crude estimate)
Raised fasting blood glucose (>=7.0 mmol/L) (age-standardized estimate)
Prevalence of insufficient physical activity among adults aged 18+ years (age-standardized estimate) (%)
Prevalence of insufficient physical activity among school going adolescents aged 11-17 (crude estimate)
Mean fasting blood glucose (mmol/l) (age-standardized estimate)
Total NCD Deaths (in thousands)
Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease
Premature deaths due to noncommunicable diseases (NCD) as a proportion of all NCD deaths (%)
Mean total cholesterol,  crude
Prevalence of insufficient physical activity among adults aged 18+ years (crude estimate) (%)
Mean total cholesterol,  age-standardized
Mean Non-HDL cholesterol, crude
Mean Non-HDL cholesterol, age-standardized
Mean HDL cholesterol, crude
Mean HDL cholesterol, age-standardized
Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, age-standardized
Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, age-standardized
Prevalence of hypertension among adults aged 30-79 years, age-standardized
Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, age-standardized
Prevalence of controlled hypertension among adults aged 30-79 years with hypertension, crude
Prevalence of previous diagnosis of hypertension among adults aged 30-79 with hypertension, crude
Prevalence of hypertension among adults aged 30-79 years, crude
Prevalence of treatment (taking medicine) for hypertension among adults aged 30-79 with hypertension, crude
General availability of colon cancer screening at the primary health care level
General availability of breast cancer screening (by palpation or mammogram) at the primary health care level
General availability of cervical cytology at the primary health care level
General availability of total cholesterol measurement at the primary health care level
General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level
General availability of urine testing for albumin
General availability of ACE inhibitors in the public health sector
General availability of aspirin (100 mg) in the public health sector
General availability of bronchodilators in the public health sector
General availability of CC blockers in the public health sector
General availability of insulin in the public health sector
General availability of metformin in the public health sector
General availability of nicotine replacement therapy in the public health sector
General availability of oral morphine in the public health sector
General availability of statins in the public health sector
General availability of steroid inhalers in the public health sector
General availability of thiazide diuretics in the public health sector
Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs
Existence of population-based cancer registry
Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets
Existence of operational policy/strategy/action plan for chronic respiratory diseases
Existence of operational policy/strategy/action plan for diabetes
Existence of operational policy/strategy/action plan for cardiovascular diseases
Existence of operational policy/strategy/action plan for cancer
Existence of operational policy/strategy/action plan to decrease tobacco use
Existence of operational policy/strategy/action plan to reduce physical inactivity
Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol
Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs
Existence of a national multisectoral commission, agency or mechanism for NCDs
Existence of a set of national NCD indicators and has set time-bound national targets for these indicators
Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors
Existence of any policies on marketing of foods to children
Existence of any policies to reduce population salt consumption
Implementation of diet and/or physical activity public awareness program
General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level
General availability of diabetes testing (by HbA1c) at the primary health care level
Existence of a diabetes registry
Has a STEPS survey or a comprehensive health examination survey every 5 years
Existence of national screening program for breast cancer
Existence of national screening program for cervical cancer
Most widely used screening method in national cervical cancer screening program
Type of national cervical cancer screening program
Coverage of national cervical cancer screening program (%)
Existence of national HPV vaccination programme
General availability of retinal photocoagulation in the public health system
General availability of dialysis in the public health system
General availability of renal replacement by transplantation in the public health system
General availability of coronary bypass or stenting in the public health system
General availability of thrombolytic therapy in the public health system
General availability of beta blockers in the public health sector
General availability of sulphonylurea(s) in the public health sector
Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities
General availability of palliative care in community or home-based care in the public health system
General availability of palliative care in primary health care in the public health system
Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities
Availability of cardiovascular risk stratification in 50% or more primary health care facilities
Existence of a set of time-bound national targets based on WHO guidance
Existence of operational policy/strategy/action plan for oral health
Implementation of physical activity public awareness program
Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach
Existence of a register of patients who had rheumatic fever and rheumatic heart disease
Has systems for follow-up/recall to deliver long-term penicillin prophylaxis to patients with rheumatic fever and rheumatic heart disease
Existence of tax on sugar-sweetened beverages
Existence of national policies on saturated fatty acids
Existence of national policies on trans-fatty acid elimination
General availability of Angiotensin II receptor blockers (ARBs) in the public health sector
General availability of bone marrow transplantation in the public health system
Existence of tax on foods high in fat, sugars or salt
Existence of price subsidies for healthy foods
Existence of tax incentives to promote physical activity
Existence of operational policy/strategy/action plan for eye health
Existence of operational policy/strategy/action plan for hearing health
Existence of operational policy/strategy/action plan to reduce overweight/obesity
Existence of national guidelines for physical activity
Implementation of a recent mass participation event
Implementation of a nutrition public awareness program
Existence of a national target on NCD mortality
Existence of a national target on alcohol
Existence of a national target on physical inactivity
Existence of a national target on salt
Existence of a national target on tobacco
Existence of a national target on blood pressure / hypertension
Existence of a national target on diabetes
Existence of a national target on obesity
Existence of a national target on drug therapy and counselling
Existence of a national target on essential medicines and technologies
Has conducted a recent, national adult risk factor survey covering harmful alcohol use
Has conducted a recent, national adult risk factor survey covering tobacco use
Has conducted a recent, national adult risk factor survey covering unhealthy diet
Has conducted a recent, national adult risk factor survey covering physical inactivity
Has conducted a recent, national adult risk factor survey covering raised blood glucose/diabetes
Has conducted a recent, national adult risk factor survey covering raised total cholesterol
Has conducted a recent, national adult risk factor survey covering raised blood pressure/hypertension
Has conducted a recent, national adult risk factor survey covering salt/sodium intake
Has conducted a recent, national adult risk factor survey covering overweight and obesity
General availability of dilated fundus examination at the primary health care level
General availability of foot vibration perception by tuning fork at the primary health care level
General availability of urine strips for glucose and ketone measurement at the primary health care level
General availability of blood pressure measurement at the primary health care level
General availability of peak flow measurement at the primary health care level
General availability of spirometry at the primary health care level
General availability of Fixed dose combination avail (lisinopril + amlodipine) in the public health sector
General availability of Fixed dose combination avail (lisinopril + hydrochlorothiazide) in the public health sector
General availability of Fixed dose combination avail (telmisartan + amlodipine) in the public health sector
General availability of Fixed dose combination avail (telmisartan + hydrochlorothiazide) in the public health sector
General availability of combination budesonide formoterol inhaler in the public health sector
General availability of diabetic retinopathy screening in the public health system
General availability of alteplase for acute stroke management in the public health system
Existence of evidence-based national guidelines/protocols/standards for the management of cardiovascular diseases
Existence of evidence-based national guidelines/protocols/standards for the management of diabetes
Existence of evidence-based national guidelines/protocols/standards for the management of cancer
Existence of evidence-based national guidelines/protocols/standards for the management of chronic respiratory diseases
Existence of evidence-based national guidelines/protocols/standards for the management of alcohol use disorders
Existence of evidence-based national guidelines/protocols/standards for the management of tobacco dependence
Existence of evidence-based national guidelines/protocols/standards for the management of overweight/obesity
Existence of evidence-based national guidelines/protocols/standards for the management of physical inactivity
General availability of cancer centres or cancer departments at tertiary level in the public sector
General availability of pathology services (laboratories) in the public sector
General availability of cancer surgery in the public sector
General availability of chemotherapy in the public sector
General availability of radiotherapy in the public sector
Existence of national guidelines for physical activity for children under 5
Existence of national guidelines for physical activity for adults
Existence of national guidelines for physical activity for children and adolescents aged 5-19
Existence of national guidelines for physical activity for older adults
Existence of policy promoting physical activity: walking and cycling
Existence of policy promoting physical activity: workplace initiatives
Existence of policy promoting physical activity: active ageing
Existence of policy promoting physical activity: community-based and sports initiatives
Existence of policy promoting physical activity: public open spaces
Existence of policy promoting physical activity: childcare settings
Annual incidence of dracunculiasis cases
Dracunculiasis certification status of countries at the beginning of the year
Status of elimination of trachoma as a public health problem
Status of endemicity of buruli ulcder
Type of nomenclature system
Health technology (medical device) national policy
Unit in the Ministry of Health responsible for the management of medical devices
Procurement of medical devices carried out at the national level
Availability of national list of approved medical devices for procurement or reimbursement
National guidelines, policies or recommendations on the procurement of medical devices
Availability of technical specifications of medical devices to support procurement or donations
Types of lists recommending health technology for high burden diseases
Use of nomenclature system
Total density per million population: Linear Accelerator
Total density per million population: Telecobalt Unit
Total density per million population: Radiotherapy units
Human development index rank
Gender inequality index rank
ICT Development Index (IDI) rank
ICT Development Index (IDI)
Percentage of individuals using the Internet
Mobile-cellular telephone subscriptions per 100 inhabitants
Civil registration coverage of cause-of-death (%)
Ill-defined causes in cause-of-death registration (%)
Overweight prevalence among children under 5 years of age (% weight-for-height >+2 SD), model-based estimates
Stunting prevalence among children under 5 years of age (% height-for-age <-2 SD), model-based estimates
Overweight prevalence among children under 5 years of age (% weight-for-height >+2 SD), survey-based estimates
Stunting prevalence among children under 5 years of age (% height-for-age <-2 SD), survey-based estimates
Underweight prevalence among children under 5 years of age   (% weight-for-age <-2 SD), survey-based estimates
Wasting prevalence among children under 5 years of age (% weight-for-height <-2 SD), survey-based estimates
Severe wasted prevalence among children under 5 years of age   (% weight-for-height <-3 SD), survey-based estimates
Tax administration: Bans or limits on duty free imports by travellers
Tax administration: Tax stamps applied on tobacco products
Tobacco excises increased over the survey period
Average - taxes as a % of cigarette price - other taxes
Average - taxes as a % of cigarette price - specific excise
Average - taxes as a % of cigarette price - total tax
Average - taxes as a % of cigarette price - ad valorem excise
Average - taxes as a % of cigarette price - value added tax
Average - taxes as a % of cigarette price - import duties
Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks)
National agency for tobacco control exists
National tobacco control budget - currency reported
Number of full-time equivalent staff in national agency
Annual budget for tobacco control in currency reported
Government objectives on tobacco control exist
Subnational smoking bans - at least one jurisdiction has a comprehensive ban in place
Most sold brand of cigarettes - taxes as a % of price - ad valorem excise
Affordability - percentage of GDP per capita required to purchase 2000 cigarettes of the most sold brand
Specific tax component automatically adjusted for inflation (or other)
Tax structure: Excise tax proportion of price
Type of excise tax applied.
Uniform excise tax applied Yes (Uniform), No (Tiered/varying rates)
Most sold brand of cigarettes - taxes as a % of price - import duties
Most sold brand of cigarettes - taxes as a % of price - other taxes
Most sold brand of cigarettes - taxes as a % of price - specific excise
Most sold brand of cigarettes - taxes as a % of price - total tax
Most sold brand of cigarettes - taxes as a % of price - value added tax
Tobacco tax revenues - currency reported
Tobacco tax revenues - total excise (specific and ad valorem)
Tobacco tax revenues - tobacco product types included
Tobacco tax revenues - year reported
Cheapest brand of cigarettes - currency reported
Premium brand of cigarettes - currency reported
Premium brand of cigarettes - price in currency reported
Estimate of current tobacco use prevalence (%)
Estimate of current cigarette smoking prevalence (%)
Most sold brand of cigarettes - price in currency reported
Most sold brand of cigarettes - currency reported
Minimum specific tax applied in ad valorem or mixed excise regime
Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT)
Greater reliance on specific tax  in mixed excise regime
Formative research was conducted prior to the campaign
Outcome evaluation was employed to assess effectiveness of the campaign
Campaign was part of a comprehensive tobacco control programme
Campaign was pre-tested
Campaign utilized media planning
At least one national mass media campaign ran during the survey period
Earned media/public relations were used to promote the campaign
Campaign ran on both national television and radio
Ban on advertising on national television and radio
Ban on promotional discounts
Ban on identifying non-tobacco products with tobacco brand names
Ban on use of brand name of non-tobacco product for tobacco product
Ban on appearance of tobacco brands in TV and/or films (product placement)
Ban on appearance of tobacco products in TV and/or films
Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images
Ban on sponsorship (contributions and/or publicity of contributions)
Ban on any form of contribution (financial or other support) to any event, activity or individual
Banning the publicity of financial or other sponsorship or support by the tobacco industry of events, activities, individuals
Ban on tobacco companies funding or making contributions (including in-kind contributions) to smoking prevention media campaigns, including those directed at youth
Ban on advertising on international television and radio
Ban on internet sales of tobacco products
Ban on advertising in local magazines and newspapers
Ban on advertising in international magazines and newspapers
Ban on billboard and outdoor advertising
Ban on product display at point of sale
Ban on advertising on the internet
Ban on free distribution in mail or through other means
Smoking cessation support is available in the community
Smoking cessation support is available in health clinics or other primary care facilities
Smoking cessation support is available in hospitals
Smoking cessation support is available in offices of health professionals
Smoking cessation support is available in other settings
Bupropion - cost covered
Bupropion - legally sold
Bupropion - place available
Smoking cessation support is cost-covered in the community
Smoking cessation support is cost-covered in health clinics or other primary care facilities
Smoking cessation support is cost-covered in hospitals
Smoking cessation support is cost-covered in offices of health professionals
Smoking cessation support is cost-covered in other settings
Nicotine replacement therapy - on the Essential Medicines List
Nicotine replacement therapy - cost covered
Nicotine replacement therapy - legally sold
Nicotine replacement therapy - place available
Access to a toll-free quit line
Varenicline - cost covered
Varenicline - legally sold
Varenicline - place available
Number of places smoke-free (national legislation)
Smoke-free health-care facilities (national legislation)
Subnational smoke-free legislation authority exists
Fines for violations of smoke-free laws
Fines on the establishment for violations of smoke-free laws
Fines on the patrons of establishments for violations of smoke-free laws
Dedicated funds for enforcement of smoke-free laws
Citizen complaints and investigations of violations of smoke-free laws
Smoke-free education facilities except universities (national legislation)
Smoke-free universities (national legislation)
Smoke-free government facilities (national legislation)
Smoke-free indoor offices (national legislation)
Smoke-free restaurants (national legislation)
Smoke-free pubs, bars and cafés (national legislation)
Smoke-free public transport (national legislation)
Smoke-free other indoor public places (national legislation)
Law mandates that health warnings appear on cigarette packages
Law mandates that health warnings appear on other smoked tobacco packages
Law mandates that health warnings appear on smokeless tobacco packages
Health warnings on cigarette packaging must include a photograph or graphic
Health warnings on other smoked tobacco packaging must include a photograph or graphic
Health warnings on smokeless tobacco packaging must include a photograph or graphic
Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale
Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale
Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale
Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale
Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale
Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale
Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry
Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry
Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry
Health warnings on cigarette packaging describe the harmful effects of tobacco use on health
Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health
Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health
Specific health warnings are mandated for cigarette packaging
Specific health warnings are mandated for other smoked tobacco packaging
Specific health warnings are mandated for smokeless tobacco packaging
Number of health warnings approved by the law for cigarette packaging
Number of health warnings approved by the law for other smoked tobacco packaging
Number of health warnings approved by the law for smokeless tobacco packaging
Health warnings on cigarette packaging law requires or establishes fines for violations
Health warnings on other smoked tobacco packaging law requires or establishes fines for violations
Health warnings on smokeless tobacco packaging law requires or establishes fines for violations
Ban on deceitful terms on cigarette packaging
Ban on deceitful terms on other smoked tobacco packaging
Ban on deceitful terms on smokeless tobacco packaging
Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors
Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors
Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors
Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging
Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging
Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging
Cigarette packaging and labelling must not use descriptors depicting flavours
Other smoked tobacco packaging and labelling must not use descriptors depicting flavours
Smokeless tobacco packaging and labelling must not use descriptors depicting flavours
Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark
Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark
Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark
Cigarette packaging and labelling must display qualitative information on emission yields
Other smoked tobacco packaging and labelling must display qualitative information on emission yields
Smokeless tobacco packaging and labelling must display qualitative information on emission yields
Emission yields must be displayed on one or more principle display areas of cigarette packaging
Emission yields must be displayed on one or more principle display areas of other smoked tobacco packaging
Emission yields must be displayed on one or more principle display areas of smokeless tobacco packaging
Display of expiry dates is prevented on cigarette packaging
Display of expiry dates is prevented on other smoked tobacco packaging
Display of expiry dates is prevented on smokeless tobacco packaging
The quit line number must appear on cigarette packaging or labelling
The quit line number must appear on other smoked tobacco packaging or labelling
The quit line number must appear on smokeless tobacco packaging or labelling
Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited)
Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited)
Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited)
Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging
Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging
Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging
Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging
Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging
Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging
Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package
Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package
Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package
Font style, font size and colour of health warnings are mandated for cigarette packaging
Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging
Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging
Health warnings on cigarette packaging must be rotated
Health warnings on other smoked tobacco packaging must be rotated
Health warnings on smokeless tobacco packaging must be rotated
Health warnings on cigarette packaging must be written in the principal language(s) of the country
Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country
Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country
Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps
Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps
Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps
Enforce bans on tobacco advertising
Monitor
Offer help to quit tobacco use
Protect from tobacco smoke
Raise taxes on tobacco
Warn about the dangers of tobacco
Anti-tobacco mass media campaigns
Cytisine - legally sold
Cytisine - place available
Cytisine - cost covered
Compliance with ban on advertising on national television and radio (score)
Compliance with ban on promotional discounts (score)
Compliance with ban on use of brand name of non-tobacco product for tobacco product (score)
Compliance with ban on indentifying non-tobacco products with tobacco brand names (score)
Compliance with ban on appearance of tobacco brands in TV and/or films (score)
Compliance with ban on appearance of tobacco products in TV and/or films (score)
Compliance with ban on sponsorship (contributions and/or publicity of contributions) (score)
Compliance with ban on advertising in local magazines and newspapers (score)
Compliance with ban on billboard and outdoor advertising (score)
Compliance with ban on advertising at point of sale (score)
Compliance with ban on free distribution in mail or through other means (score)
Overall compliance with regulations on smoke-free environments (score)
Compliance with smoke-free health-care facilities law (score)
Compliance with smoke-free education facilities except universities law (score)
Compliance with smoke-free universities law (score)
Compliance with smoke-free government facilities law (score)
Compliance with smoke-free indoor offices law (score)
Compliance with smoke-free restaurants law (score)
Compliance with smoke-free pubs and bars law (score)
Compliance with smoke-free public transport law (score)
Year of most recent survey of adults
Representativeness of most recent survey of adults
Age range of most recent survey of adults
Title of most recent survey of adults
Name of latest adult prevalence survey (nonsmoked)
Year of latest adult prevalence survey (nonsmoked)
Representation of latest adult prevalence survey (nonsmoked)
Age range of latest adult prevalence survey (nonsmoked)
Prevalence of current tobacco use among adults (%)
Prevalence of daily tobacco use among adults (%)
Prevalence of current tobacco smoking among adults (%)
Prevalence of daily tobacco smoking among adults (%)
Prevalence of current cigarette smoking among adults (%)
Prevalence of daily cigarette smoking among adults (%)
Prevalence of current smokeless tobacco use among adults (%)
Prevalence of daily smokeless tobacco use among adults (%)
Prevalence of current e-cigarette use among adults (%)
Prevalence of daily e-cigarette use among adults (%)
Ban on sale of duty-free or excise-free cigarettes
Affordability – category of change 2010-2020 (Yes (less affordable), No (more affordable), No change).
Reported use of earmarked tobacco taxes
Tax stamps, fiscal marks, banderole or other types of marking are applied on cigarettes
Tax stamps, fiscal marks, banderole or other types of marking are applied on other tobacco products
A minimum price policy is implemented
Cheapest brand of cigarettes - price in currency reported
Cheapest brand of cigarettes - price in PPP$
Cheapest brand of cigarettes - price in US$ at official exchange rates
Most sold brand of cigarettes - price in PPP$
Most sold brand of cigarettes - price in US$ at official exchange rates
Premium brand of cigarettes - price in PPP$
Premium brand of cigarettes - price in US$ at official exchange rates
Prevalence of current smokeless tobacco use among adolescents (%)
Prevalence of current e-cigarette use among adolescents (%)
Prevalence of current cigarette smoking among adolescents (%)
Estimate of current tobacco use prevalence (%) (age-standardized rate)
Estimate of current tobacco smoking prevalence (%)
Estimate of current tobacco smoking prevalence (%) (age-standardized rate)
Estimate of current cigarette smoking prevalence (%) (age-standardized rate)
Title of most recent adolescent survey
Year of most recent adolescent survey
Representativeness of most recent adolescent survey
Name of latest youth prevalence survey (nonsmoked)
Year of latest youth prevalence survey (nonsmoked)
Representation of latest youth prevalence survey (nonsmoked)
Age range of latest youth prevalence survey (nonsmoked)
Age range of most recent adolescent survey
Process evaluation was employed to assess implementation of the campaign
Overall compliance with bans on promotion and sponsorship (score)
Ban on Corporate Social Responsibility activities (CSR)
Ban on tobacco companies/the tobacco industry publicizing their CSR activities
Ban on entities other than tobacco companies/the tobacco industry publicizing the CSR activities of the tobacco companies/industry
Law requires fines for violations of advertising bans
Law requires fines for violations of promotion and sponsorship bans
Subnational bans on tobacco advertising, promotion and sponsorship authority exists
Ban on tobacco vending machines
Ban on advertising at point of sale
Overall compliance with bans on direct advertising (score)
Status of bejel endemicity
Status of pinta endemicity
Number of cases of cutaneous leishmaniasis reported
Status of yaws endemicity
Status of endemicity of cutaneous leishmaniasis
Status of endemicity of visceral leishmaniasis
Number of imported cases of cutaneous leishmaniasis reported
Legislation
Coordination
Surveillance
Response
Preparedness
Risk communication
Human resources
Laboratory
Points of entry
Zoonosis
Food safety
Chemical
Radionuclear
Alcohol-related road traffic crashes with fatalities, per 100,000  population
Electric field (kV/m)
Electric field (kV/m) low frequency
Alcohol-related crimes (% of all crimes)
National drinking guidelines,2016
Alcohol, total per capita (15+) consumption (in litres of pure alcohol) with 95%CI
Food Safety (SPAR)
Surveillance (SPAR)
Risk Communication (SPAR)
Human Resources (SPAR)
Laboratory (SPAR)
Points of Entry (SPAR)
Compliance with international health regulations
UHC Service Coverage Index (SDG 3.8.1)
UHC Service Coverage sub-index on service capacity and access
UHC Service Coverage sub-index on reproductive, maternal, newborn and child health
UHC Service Coverage sub-index on infectious diseases
UHC Service Coverage sub-index on noncommunicable diseases
Primary data availability for UHC Service Coverage Index (SDG 3.8.1) (%)
Donor/ non-public development funding for eHealth
Proportion of donor/non public development funding
Government-supported health internet sites provide information in multiple languages
Institutions offer in-service training to health professionals on ICT for health
Proportion ofpublic private partnerships funding
strategy refers to the use of ICT to support UHC
Proportion of public funding
Public funding for eHealth
Strategy implementation funding available for eHealth
Private funding for eHealth
Tertiary institutions provide students of health sciences with training on eHealth
National  health information system (HIS) policy or strategy
Public-private partnerships for eHealth
Proportion of private funding
National universal health coverage strategy
National eHealth strategy refers to objectives of UHC
National eHealth strategy
Demand
Cost-effectiveness
Regulating mobile devices and software
Promoting the development and adoption of mHealth
Government-sponsored mHealth programmes are being evaluated
Promoting standards and interoperability
mHealth programmes are sponsored by government
Funding
Capacity
Legal
Infrastructure
Providing guidance on privacy and security
Providing incentives and guidance for innovation research and evaluation of health
Effectiveness
Regulatory oversight of mobile apps for quality, safety and reliability
Providing oversight and enforcement of data ownership
Policy
Priorities
Country has telehealth policy or strategy
Evaluation of any government-sponsored telehealth programmes
Strategy includes objectives as to how telehealth contributes to UHC
eLearning is used in pre-service education to teach health sciences students
Lack of evidence over cost-effectiveness
eLearning programmes for in-service training of health professionals have been evaluated
Improving access to content and experts (in-service)
eLearning used for in-service training of health professionals
Insitutional educational policy does not include eLearning as an approach to teaching health sciences
Lack of demand for eLearning programmes
Improving access to content and experts (pre-service)
Competing educational priorities
Lack of capacity
Pre-service eLearning programmes have been evaluated
Reducing cost of delivering content (pre-service)
eLearning courses accredited by continuing medical education or professional licensing bodies
Lack of suitable courses available
Reducing cost of delivering content (in-service)
Enabling access to education where learning facilities are limited (pre-service)
Lack of funding
Lack of evidence that eLearning is effective
Enabling access to education where learning facilities are limited (in-service)
Not possible to gain a health sciences degree entirely through eLearning
Lack of infrastructure
National strategy does not promote the adoption of EHR
Lack of evidence showing cost-effectiveness or EHR
Lack of capacity (for EHR)
Country has specific legislation governing the use of national EHR system
Lack of infrastructure (for EHR)
Lack of funding (for EHR)
Competing health system priorities
Lack of national or international standards for interoperability of EHR
Country has national EHR
lack of evidence showing effectiveness of EHR
Lack of demand by health professionals and patients
Lack of legislation or regulations covering use of EHR
to protect the privacy of individuals' health-related  data held in electronic format as an EHR
which allows for the sharing of personal and health data between research entities
which allows individuals to demand that their own data be corrected  when held in an EHR if it is known to be inaccurate
Policy or strategy makes specific reference tothe use of social media in the health domain
to define medical jurisdiction, liability or reimbursement of eHealth services such as telehealth
which governs the sharing of digital data between health professionals  in health services in other countries through the use of an EHR
Individuals have the legal right to specify which health-related data from their EHR can be shared with health professionals of their choice
to address patient safety and quality of care based on data quality, data transmission standards, or clinical competency criteria
which allows individuals to demand the deletion of health-related data from their EHR
which governs the sharing of digital data between health professionals in other health services in the same country through the use of an EHR
Country has national policy or strategy on the use of social media by government organizations
which allows individuals electronic access to their own health-related data when held in an EHR
to protect privacy of personally identifiable data of individuals irrespective of whether it is paper or digital format
Effective standards and best practices for data capture not fully established
Research into new analytical methods needs occur to meet the challenges of working with big data
Country has national policy or strategy regulating the use of big data by private companies
Capacity building required for new skills
Lack of integration between various health services
Insufficient incentives for data sharing
Country has  national policy or strategy regulating the use of big data in the health sector
Privacy and security laws need to be in place
Government unit/official responsible for prevention for substance use
Ministry/office that takes primary responsibility for prevention for substance use
Five years change in international cooperation for prevention for substance use
Government unit/official responsible for treatment of substance use disorders
Ministry/office that takes primary responsibility for treatment of substance use disorders
Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for treatment of substance use disorders
Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for treatment of substance use disorders
Involvement of representatives of affected or targeted populations in the development and formulation of policies and strategies for prevention for alcohol and drugs
Involvement of representatives of affected or targeted populations in the development and implementation of national programmes for prevention for alcohol and drugs
Five years change in international cooperation for treatment of substance use disorders
Confidentiality of people in treatment for substance use disorders
Voluntary treatment for people with alcohol use disorders in the criminal justice system
Compulsory treatment for people with alcohol use disorders in the criminal justice system
Compulsory treatment for people with drug use disorders in the criminal justice system
Voluntary treatment for people with drug use disorders in the criminal justice system
Five-year change in government resources for prevention for substance use
Five-year change in government resources for treatment of substance use disorders
Financing methods for treatment for alcohol use disorders
Financing methods for treatment for drug use disorders
Government benefits for people with alcohol use disorders
Government benefits for people with drug use disorders
Hypothecated taxes to be spent on prevention and treatment for substance use disorders
Main sector for treatment for drug use disorders
Treatment programmes for children and adolescents with alcohol use disorders (treatment)
Treatment programmes for children and adolescents with drug use disorders (treatment)
Specialized treatment facilities for substance use disorders
Specialized treatment facilities for alcohol use disorders
Specialized treatment facilities for drug use disorders
Self-help groups
Main sector for treatment for alcohol use disorders
Main substance at treatment entry
Reported treatment coverage for substance dependence
Guidelines on pharmacological treatment for substance use disorders
Pharmacotherapy with methadone
Pharmacotherapy with buprenorphine
Pharmacotherapy with buprenorphine/naloxone
Access restrictions to maintenance treatment
Timeframe for maintenance treatment of opioid dependence
Registration of medications for alcohol dependence and withdrawal
Registration of medications for opioid dependence
Registration of medications for opioid withdrawal
Registration of naloxone for injection for opioid overdose
Availability of naloxone
Screening and brief intervention for substance use in primary health care
Screening and brief intervention for substance use in antenatal services
Recommendations for screening and brief interventions for substance use in primary health care
Recommendations for screening and brief interventions for substance use in antenatal services
Groups and agencies involved in prevention programs
Prevention programmes for alcohol
Prevention programmes for specific populations for alcohol
Prevention programmes for drugs
Prevention programmes for specific populations for drugs
HIV, Hepatitis counselling and treatment availability in specialized facilities and services
Programmes readily available
Standards of treatment and care for public specialized treatment facilities
Special treatment programmes for gambling disorder
Treatment programmes for women with alcohol use disorders
Treatment programmes for women with drug use disorders
Special housing services for alcohol use disorders
Special housing services for drug use disorders
Employment services for alcohol use disorders
Employment services for drug use disorders
Open access interventions for alcohol
Open access interventions for drugs
Health professionals providing treatment for alcohol and drug use disorders
Standards of care for professionals providing treatment for alcohol and drug use disorders
Educational attainment in prevention
Postgraduate training programme in prevention
Continuing professional development in prevention
Educational attainment in treatment
Postgraduate training programme in treatment
Continuing professional development in treatment
Epidemiological data collection for substance use
Service delivery data collection for substance use
Regular reports on epidemiological and service delivery data for substance use
Epidemiological data collection system for substance use among children and adolescents (see RSUD_880)
System of monitoring alcohol involvement in forensic pathology
System of monitoring drugs involvement in forensic pathology
Epidemiological data collection system for substance use among children and adolescents
Treatment programmes for children and adolescents with alcohol use disorders (youth)
Treatment programmes for children and adolescents with drug use disorders (youth)
Availability of estimates on impoverishment due to out-of-pocket health expenditures
Availability of estimates on large health expenditures as a share of total expenditure or income
Population with household spending on health greater than 10% of total household budget (SDG 3.8.2, reported data) (%)
Population with household spending on health greater than 25% of total household budget (SDG 3.8.2, reported data) (%)
Population pushed below the $1.90 a day poverty line by household health expenditures (%)
Population pushed below the $3.20 a day poverty line by household health expenditures (%)
Population pushed below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%)
Population pushed further below the $1.90 a day poverty line by household health expenditures (%)
Population pushed further below the $3.20 a day poverty line by household health expenditures (%)
Population pushed further  below a relative poverty line by household health expenditures (60% of median daily per capita consumption or income) (%)
Increase in poverty gap due to household health expenditures, expressed as a proportion of the $1.90 a day poverty line (%)
Increase in poverty gap due to household health expenditures, expressed as a proportion of the $3.20 a day poverty line (%)
Increase in poverty gap due to household health expenditures, expressed as a proportion of a relative poverty line (60% of median daily per capita consumption or income) (%)
Number of deaths attributed to non-communicable diseases, by type of disease and sex
Nursing personnel (number)
Midwifery personnel (number)
Dental Assistants and Therapists (number)
Pharmaceutical Technicians and Assistants (number)
Medical and Pathology Laboratory scientists (number)
Medical and Pathology Laboratory Technicians (number)
Physiotherapists (number)
Physiotherapy Technicians and Assistants (number)
Medical doctors (%)
Nursing personnel (%)
Medical doctors not further defined (number)
Medical doctors (number)
Medical doctors (per 10 000 population)
Nursing and midwifery personnel  (number)
Dentists (number)
Dentists (per 10 000 population)
Pharmacists (number)
Pharmacists  (per 10 000 population)
Nursing and midwifery personnel (per 10 000 population)
Reporting countries
Proportion of isolates with resistance to azithromycin reported to WHO-GASP
Proportion of isolates with decreased susceptibility or resistance (DS/R) to cefixime reported to WHO-GASP
Proportion of isolates with resistance to ciprofloxacin reported to WHO-GASP
Proportion of isolates with decreased susceptibility or resistance (DS/R) to ceftriaxone reported to WHO-GASP
Proportion of isolates with decreased susceptibility or resistance (DS/R) to extended-spectrum cephalosporins reported to WHO-GASP
Number of isolates tested for azithromycin
Number of isolates tested for cefixime
Number of isolates tested for ciprofloxacin
Number of isolates tested for ceftriaxone
Number of isolates tested for extended-spectrum cephalosporins
ICD-11 implementation progress level
Institutional Births (birth taken place in a facility) (%)
Number of reported cases of poliomyelitis by wild poliovirus (WPV)
Births in baby-friendly facilities (%)
Nutrition Governance score
International Code on Marketing of Breast-milk Substitutes: Legal status of the Code
Maternity protection: Compliance with international labour standards
GDP per capita annual growth rate (%)
